Potential role of pharmacogenomics in reducing adverse drug reactions: a systematic review.

By K. Phillips, D. Veenstra, E. Oren, Jane K. Lee, W. Sadee. Journal of the American Medical Association (JAMA), 2001

749 citations recorded by the source corpus.

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

Pharmacogenomics and individualized drug therapy. (2006, background): “For example, of 27 drugs frequently cited in ADR studies, 59% are metabolized by at least one enzyme with a variant allele associated with decreased drug metabolism (8).”
Moving towards individualized medicine with pharmacogenomics (2004, background): “To some extent, this is related to the perceived high cost of genotyping, even though this process has been shown to be cost-effectiv”
Pharmacogenomics of Drug Metabolizing Enzymes and Transporters: Relevance to Precision Medicine (2016, background): “Different CYP allelic variants significantly contribute to the variability of an individual’s susceptibility to drug–drug interactions and drug-metabolizing capacities [161].”
Predicting in vivo drug interactions from in vitro drug discovery data (2005, background): “Allelic variants of CYP enzymes have been shown to have pronounced variability in drug-metabolizing capacity and therefore have the potential to increase a patient's susceptibility to adverse DDI”
Association between CYP2C9 genetic variants and anticoagulation-related outcomes during warfarin therapy. (2002, background): “As genomic information becomes more readily available, it is likely that clinicians will need to consider new guidelines for patient management, especially when administering drugs with narrow therapeutic indexes such as warfarin.(34,35) Variant CYP2C9 genotype could be considered a “sensitivity fac”